公开(公告)号：US12065663B2

公开(公告)日：2024-08-20

申请号：US17812425

申请日：2022-07-13

Applicant: CHIGENOVO CO., LTD

Inventor： Liping Yang ,  Shaohong Chen ,  Ruixuan Jia ,  Fan Zhang ,  Saichao He ,  Tianyong Shi ,  Dandan Hao ,  Hongjie Pei ,  Luying Zeng

IPC: C12N15/86 ,  A61K48/00 ,  A61P27/02 ,  C12N9/02

CPC classification number: C12N15/86 ,  A61P27/02 ,  C12N9/0071 ,  A61K48/00 ,  C12N2750/14143

Abstract: The present application relates to a vector comprising a polynucleotide encoding CYP4V2 and a promoter operably linked to the polynucleotide encoding CYP4V2. The vector described herein has a good expression effect, high expression speed, and more stable expression intensity. The present application also provides cells, pharmaceutical compositions, and kits comprising the vector, and methods for treating, alleviating, and/or preventing a disease or disorder associated with retinal pigment epithelium (RPE) atrophy.

公开(公告)号：US12064420B2

公开(公告)日：2024-08-20

申请号：US17569838

申请日：2022-01-06

Applicant: EyePoint Pharmaceuticals, Inc.

Inventor： Kevin Peters

IPC: A61K31/426 ,  A61K9/00 ,  A61P27/02

CPC classification number: A61K31/426 ,  A61P27/02 ,  A61K9/0048

Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions, for example, intraocular pressure, ocular hypertension, and glaucoma.

公开(公告)号：US20240270799A1

公开(公告)日：2024-08-15

申请号：US17913769

申请日：2021-03-24

Applicant: NATIONAL UNIVERSITY CORPORATION, IWATE UNIVERSITY

Inventor： Hiroshi TOMITA ,  Eriko SUGANO

IPC: C07K14/405 ,  A61K38/00 ,  A61P27/02 ,  C12N15/86

CPC classification number: C07K14/405 ,  A61P27/02 ,  C12N15/86 ,  A61K38/00 ,  C07K2319/03 ,  C12N2750/14143

Abstract: An object of the present invention is to provide a modified photoreceptive chloride channel having excellent photoreactive properties in which the wavelength sensitivity range is narrow, and also both τon and τoff are short. The solution is a polypeptide obtained by substituting a region from the fourth transmembrane domain to the sixth transmembrane domain counted from the N-terminal side of a Guillardia theta-derived photoreceptive chloride channel-1 (GtACR1) by a corresponding region of a Guillardia theta-derived photoreceptive chloride channel-2 (GtACR2).

公开(公告)号：US20240261379A1

公开(公告)日：2024-08-08

申请号：US18562810

申请日：2022-05-19

Applicant: GRANDPHARMA (CHINA) CO., LTD. ,  BRIM Biotechnology, Inc.

Inventor： Lei LI ,  Yimin HU ,  Hui ZHAN ,  Caiyun XIANG ,  Lei QU ,  Wei-Cheng LIAW ,  Huei-Ling CHANG ,  Chih-Te CHIEN ,  Yi-Lun CHIANG

IPC: A61K38/57 ,  A61K47/12 ,  A61K47/22 ,  A61K47/32 ,  A61P27/02

CPC classification number: A61K38/57 ,  A61K47/12 ,  A61K47/22 ,  A61K47/32 ,  A61P27/02

Abstract: The present invention relates to a composition, a preparation method therefor, and a use thereof. The composition comprises a PEDF-derived short peptide (PDSP), a stabilizer, and a buffer agent. The pH of the composition ranges from 4 to 9. The stabilizer is a copolymer of vinyl pyrrolidone and vinyl acetate. The buffer agent is selected from a citric acid buffer system, a phosphoric acid buffer system, a boric acid buffer system, a histidine buffer system, or a combination thereof. The composition has improved stability, small irritation to eyes, and/or high bioavailability.

公开(公告)号：US20240254213A1

公开(公告)日：2024-08-01

申请号：US18034293

申请日：2021-10-29

Applicant: Hideaki HARA ,  Masamitsu SHIMAZAWA ,  Shinsuke NAKAMURA

Inventor： Hideaki HARA ,  Masamitsu SHIMAZAWA ,  Shinsuke NAKAMURA

IPC: C07K16/22 ,  A61K39/00 ,  A61P27/02

CPC classification number: C07K16/22 ,  A61P27/02 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76

Abstract: The invention provides novel methods of treating ocular disorders that cause ocular tissue fibrosis by using a substance that inhibits the action of GDF15 (growth differentiation factor 15). In the present invention, the substance inhibiting the action of the GDF15 may be an anti-GDF15 antibody or an antagonist of a GDF15-specific receptor. Furthermore, in the present invention, the ocular tissue may be retinal pigment epithelial cells.

公开(公告)号：US12048837B2

公开(公告)日：2024-07-30

申请号：US18063918

申请日：2022-12-09

Applicant: NOVARTIS AG

Inventor： Andrew Bryant ,  Heinrich Buettgen ,  Wolfgang Papst ,  Marie Picci

IPC: A61M5/00 ,  A61M5/28 ,  A61M5/315 ,  A61P27/02 ,  A61F9/00 ,  A61M5/31

CPC classification number: A61M5/31513 ,  A61M5/001 ,  A61M5/28 ,  A61M5/31505 ,  A61P27/02 ,  A61F9/0017 ,  A61M2005/3104 ,  A61M5/3137 ,  A61M2005/3139 ,  A61M2005/31508 ,  Y10T29/49826

Abstract: The invention provides a syringe for use in an ophthalmic injection. The syringe comprises a body, a stopper and a plunger. The body comprises an outlet at an outlet end and the stopper is arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled though the outlet. The plunger comprises a plunger contact surface at a first end and a rod extends between the plunger contact surface and a rear portion. The plunger contact surface is arranged to contact the stopper but not couple thereto, such that the plunger can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, but not to move the stopper away from the outlet end.

公开(公告)号：US20240238279A1

公开(公告)日：2024-07-18

申请号：US18416302

申请日：2024-01-18

Applicant: ADS Therapeutics LLC

Inventor： Jinsong Ni ,  Rong Yang

IPC: A61K31/496 ,  A61K9/00 ,  A61K9/08 ,  A61K9/107 ,  A61K31/365 ,  A61K31/404 ,  A61K31/407 ,  A61K31/416 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/513 ,  A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/675 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/36 ,  A61K47/40 ,  A61P27/02 ,  A61P27/06

CPC classification number: A61K31/496 ,  A61K9/0048 ,  A61K9/0051 ,  A61K9/08 ,  A61K9/107 ,  A61K31/365 ,  A61K31/404 ,  A61K31/407 ,  A61K31/416 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/506 ,  A61K31/513 ,  A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/675 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/183 ,  A61K47/186 ,  A61K47/26 ,  A61K47/36 ,  A61K47/40 ,  A61P27/02 ,  A61P27/06

Abstract: Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

公开(公告)号：US20240226198A1

公开(公告)日：2024-07-11

申请号：US18027889

申请日：2021-09-17

Applicant: PBLBIOLAB ,  NVP Healthcare Co., Ltd.

Inventor： Dong Hyun Kim

IPC: A61K35/747 ,  A61K35/745 ,  A61P1/00 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  C12N1/20

CPC classification number: A61K35/747 ,  A61K35/745 ,  A61P1/00 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  C12N1/20

Abstract: The present invention relates to novel Lactobacillus plantarum, Bifidobacterium bifidum, Bifidobacterium longum or mixtures thereof, and a use thereof. Strains or mixtures thereof according to the present invention have excellent Proteobacteria expression inhibitory and anti-inflammatory effects and increase lacrimal secretion from the eyes, inhibit inflammation in the cornea and/or retina, exhibit excellent anti-oxidant and inflammation inhibitory effects in the cornea and/or retina, reduce the amount of fatigue substances in the body, and exhibit effects such as neuroinflammatory factor inhibition, BDNF expression enhancement, and cognitive disorders and mental disorder alleviation. Therefore, the present invention can be effectively used in the treatment, alleviation and prevention of eye diseases, fatigue, inflammatory diseases, cognitive disorders, mental disorders and the like.

公开(公告)号：US20240226001A1

公开(公告)日：2024-07-11

申请号：US18142017

申请日：2023-05-01

Applicant: Mitotech S.A.

Inventor： Anton Dmitrievich PETROV ,  Maxim Vladimirovich SKULACHEV ,  Vladim Neronovich TASHLITSKY ,  Elena Mirovna KARGER ,  Lawrence T. FRIEDHOFF

IPC: A61K9/00 ,  A61K31/352 ,  A61K31/36 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/66 ,  A61P27/02 ,  C07D311/82 ,  C09B11/24 ,  C09B57/00 ,  C09B69/00 ,  C11D3/00

CPC classification number: A61K9/0051 ,  A61K31/352 ,  A61K31/36 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/66 ,  A61P27/02 ,  C07D311/82 ,  C09B11/24 ,  C09B57/00 ,  C09B69/001 ,  C11D3/0078

Abstract: The present inventor has discovered how to adsorb a mitochondrially targeted compound (MTC) of general formula I on contact lenses and other matrices prior to the application of lenses or other matrix on the eye surface. After such matrix is positioned on the eye, MTC is translocated from the lens into cornea cells of the eye providing cornea protective effect and thus reducing side effects of contact lens application.

公开(公告)号：US20240217927A1

公开(公告)日：2024-07-04

申请号：US18597021

申请日：2024-03-06

Applicant: Nacuity Pharmaceuticals, Inc.

Inventor： G. Michael Wall ,  Neil Beare ,  Cory A. Black

IPC: C07C323/41 ,  A61K9/00 ,  A61K9/08 ,  A61K31/00 ,  A61K31/185 ,  A61K47/10 ,  A61P27/02 ,  C07C319/12 ,  C07C319/24 ,  C07C319/28 ,  C07D277/12

CPC classification number: C07C323/41 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/00 ,  A61K31/185 ,  A61K47/10 ,  A61P27/02 ,  C07C319/12 ,  C07C319/24 ,  C07C319/28 ,  C07D277/12 ,  C07B2200/05 ,  C07B2200/07

Abstract: The present invention includes pharmaceutical composition comprising deuterated NACA-d3, deuterated di-NACA-d6, combinations thereof, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using NACA-d3, di-NACA-d6, or combinations thereof, to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuvenation, antimicrobial infection, Friedreich's ataxia.